The Smear Machine of Public Health

There is something deeply revealing about the way parts of public health react whenever someone questions prohibitionist nicotine policy. The response is rarely curiosity. It is rarely debated. It is rarely a reflection. Instead, it descends into insinuation, guilt by association, moral panic, and coordinated character attacks.

In a LinkedIn exchange surrounding public health commentary, the Philip Morris debate, and criticism of Australia’s nicotine policies, once again exposed a culture that increasingly appears unable to distinguish disagreement from corruption. Anyone who questions the prevailing orthodoxy is rapidly framed as “industry-linked,” “Big Tobacco aligned,” or part of some hidden conspiracy. The accusation itself becomes the argument.

That is the real story.

Not science. Not outcomes. Not smoking rates. Not whether adult smokers are dying because safer nicotine products remain functionally inaccessible while cigarettes remain available in every servo, supermarket and corner store across Australia.

The real story is that sections of public health have become so ideologically captured that dissent itself is treated as contamination.

The outrage surrounding discussions involving Philip Morris revealed this mentality perfectly. Entire conversations became consumed not with the substance of the arguments being made, but with the mere fact that engagement with a tobacco company had occurred at all. It no longer mattered whether the topic was illicit trade, harm reduction, black markets, enforcement failures, youth smoking trends, taxation, organised crime, or unintended consequences of prohibition. The existence of contact itself became enough to morally disqualify discussion.

This is an extraordinary position for people who claim to support evidence-based policymaking.

In every other major field, governments, regulators and policymakers engage with industries connected to the products they regulate. Pharmaceutical companies are consulted on medicines. Alcohol producers are consulted on alcohol policy. Gambling companies are consulted on gambling regulation. Energy companies are consulted on emissions frameworks. Technology companies are consulted on online safety laws. Banks are consulted on financial regulation.

Nobody pretends these industries are saints. Nobody suggests policymakers should become corporate puppets. But mature regulatory systems understand something very basic: if you want to solve complex problems, you have to understand all parts of the system, including the uncomfortable ones.

Yet tobacco and nicotine policy has evolved into something almost theological, where engagement itself is treated as heresy.

The irony is difficult to ignore because the same public health figures who demand absolute exclusion of tobacco industry perspectives routinely operate within their own tightly interconnected networks of advocacy groups, government grants, pharmaceutical interests, university departments, NGOs, lobbying organisations and media relationships. Their own institutional incentives are rarely interrogated with equal hostility.

Public health today is not some neutral priesthood floating above politics and influence. It is an ecosystem with funding structures, ideological incentives, career pathways, reputational hierarchies and political alliances. Entire careers have been built around anti-vaping activism. Entire organisations rely on the continuation of moral panic to justify relevance, funding and media visibility.

That does not automatically invalidate their arguments. But if conflicts and incentives matter, then they matter universally, not selectively.

Instead, only one side is presumed permanently corrupted.

The implication is clear: if you oppose prohibitionist nicotine policy, your motives must be suspect.

This is not science. It is tribalism.

And tribalism has become the defining feature of contemporary tobacco control.

The moment somebody raises concerns about illicit markets, unintended consequences, youth smoking rebounds, access barriers, the criminalisation of consumers, or the failure of prohibition, the response is not engagement with the substance of the argument. The response is an attempt to delegitimise the speaker.

The Philip Morris debate exposed how quickly public health discourse now collapses into moral theatre. Rather than confronting difficult policy realities, parts of the movement instinctively shift toward policing associations, identities and perceived loyalties. Complex policy questions are reduced to simplistic binaries of good people versus bad people, pure actors versus contaminated actors, approved voices versus forbidden voices.

This allows institutions to avoid confronting uncomfortable realities.

Australia now faces an exploding illicit tobacco market. Firebombings linked to the tobacco trade have become a national issue. Organised crime groups are profiting enormously. Illegal vape supply chains have become entrenched. Consumers continue accessing products regardless of prohibition. Border seizures continue while products remain everywhere. Smoking itself is no longer declining with the certainty many once assumed.

These are policy problems requiring serious discussion.

But instead of encouraging open debate, sections of public health increasingly appear focused on controlling who is allowed to speak.

That should alarm everyone, regardless of where they stand on vaping.

A scientific culture confident in its evidence does not fear scrutiny. It does not require social ostracism to maintain authority. It does not collapse into outrage every time an uncomfortable conversation occurs. It welcomes challenge because challenge strengthens evidence.

What we are increasingly witnessing instead is ideological defensiveness masquerading as moral virtue.

The very people who accuse others of spreading misinformation often rely on emotionally manipulative campaigns, selective evidence presentation, and social shaming as core communication strategies. Public health campaigns increasingly frame vaping not through balanced risk communication but through fear, stigma, disgust and social isolation.

Consumers are not spoken to as rational adults capable of understanding relative risk. They are spoken to as potential deviants requiring behavioural correction.

Language like “renormalisation,” “gateway,” “epidemic,” and “Big Tobacco tactics” is deployed constantly because it activates emotional reflexes rather than analytical thinking. Once those emotional reflexes are activated, debate becomes almost impossible. Anyone questioning the dominant narrative can instantly be cast as morally compromised.

That matters because language shapes policy.

When every disagreement becomes “industry propaganda,” nuance dies.

When every advocate for harm reduction becomes morally tainted, evidence becomes secondary to ideological loyalty.

When public health institutions define themselves as activists first and scientists second, they stop functioning as neutral arbiters of evidence and become political actors defending institutional narratives.

And once institutions become political actors, smear campaigns become inevitable.

The public health ecosystem increasingly behaves less like a scientific field and more like an insulated social clique. Certain approved experts are elevated endlessly across the media. Certain narratives become untouchable. Certain data points are amplified while others are buried. Certain studies receive saturation coverage while contradictory evidence disappears into silence. Those who remain inside the ideological perimeter are rewarded with legitimacy. Those outside it are treated as dangerous.

This is why debates around vaping in Australia have become so toxic.

People are no longer simply arguing over evidence. They are defending identities, careers, reputations and entire institutional worldviews.

If vaping works as a disruptive harm reduction tool for millions of smokers, then decades of abstinence-only messaging begin to look incomplete. If consumers can improve their health without following the traditional quit-or-die pathway, then public health loses monopoly control over the cessation narrative. If grassroots consumer advocates have valid lived experience, then institutional expertise no longer holds exclusive moral authority.

That possibility terrifies parts of the system because it threatens not only policy positions but status structures.

So instead of adapting, they attack.

Doctors who support harm reduction are smeared. Researchers are accused of hidden allegiances. Consumers are dismissed as manipulated dupes. Former smokers who credit vaping for saving their lives are treated as anecdotal inconveniences rather than human beings. Journalists questioning the prohibition are accused of platforming industry narratives. Citizens expressing frustration online are framed as vectors of disinformation.

The objective is not persuasion. The objective is social containment.

At some point, reasonable people need to ask uncomfortable questions.

If your position is truly evidence-based, why are you so afraid of open debate?

Why does every challenge require moral condemnation?

Why must critics be psychologically or financially discredited instead of scientifically rebutted?

Why are lived experiences from former smokers treated with suspicion when they conflict with institutional messaging?

Why is discussing unintended consequences considered betrayal rather than responsible policymaking?

And perhaps most importantly, why has public health become so comfortable dehumanising people who disagree with them?

The tragedy is that this culture damages trust far beyond vaping.

When institutions weaponise smear tactics, people stop believing them even when they are correct. When public health communicates through fear and social coercion, citizens become cynical. When critics are silenced instead of engaged, the public notices. When institutions appear more interested in preserving ideological purity than solving real-world problems, trust erodes rapidly.

Australians are already watching the contradictions unfold in real time.

Cigarettes remain widely available despite killing tens of thousands annually. Governments continue collecting enormous tobacco tax revenue. Meanwhile, reduced-risk nicotine products are pushed into medicalised access systems, black markets, criminal networks and underground supply chains.

The result has been predictable: exploding illicit trade, growing distrust, enforcement chaos, expanding organised crime involvement, and increasing public confusion.

Yet instead of confronting policy failure honestly, sections of public health continue searching for villains.

The easiest villain is always the dissenter.

The easiest tactic is always the smear.

But smear campaigns are not a substitute for evidence.

And they are certainly not a substitute for humility.

Perhaps the most revealing part of the entire exchange was not the disagreement itself, but the complete absence of humility from those demanding unquestioned moral authority.